ACADIA Pharmaceuticals Inc (ACAD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $27.29 (-0.58%), Market cap $3.66B, P/E ratio 9.68, 52-week low–high $20.06 ~ $28.06.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body d
Financial statements, price targets, institutional (13F) holdings and related news for ACADIA Pharmaceuticals Inc are updated in real time on BlackAll Trade.
ACADIA Pharmaceuticals Inc trades at $27.29 (-0.58%). Real-time quotes and charts are available on BlackAll Trade.
ACADIA Pharmaceuticals Inc has a market cap of about $3.66B. Its P/E ratio is 9.68.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID